A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Germany, Spain, Finland, Greece, Portugal, Italy, Belgium, Poland, France
Condition studied
Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Investigational medicinal product(s)
JNJ-73841937JNJ-61186372
Eligibility
Age group
18-64 years, 65+ years
Sex
Female, Male
Primary endpoint
PFS according to RECIST v1.1 by investigator assessment
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.